Table 3. Cytarabine doses administered... | American Society of Hematology

Table 3.

Cytarabine doses administered to adult FLT3ITD–positive patients during induction and postremission therapy

Study	Cytarabine dose				Comment	Reference
Study	80-200 mg/m²	1 g/m²	2 g/m²	3 g/m²	Comment	Reference
AML-87	0.8-1.6 g/m²^3-150,^3-151	—	—	—	Double induction if no CR after first course	43
	3.8 g/m²^3-151,^3-152
	12.24 g/m²^3-151,^3-153
AML-89	0.32-0.96 g/m²^3-150 or	—	—	—	Double induction if no CR after first course	44
	0.8-2.4 g/m²^3-150,^3-151
	2.12 g/m²^3-152 or
	3.8 g/m²^3-151,^3-152
	6.12 g/m²^3-151,^3-153
AML-92	2 g/m²^3-150,^3-151	—	—	—	Postremission therapy not reported	45
HOVON-29	1.4 g/m²^3-150	12 g/m²^3-150	—	—	—	46
HOVON-4	1.4 g/m²^3-150	12 g/m²^3-150	—	—	—	47
AML-11	1.4-2.8 g/m²^3-150	—	—	—	Double induction if PR after first course	48
	1.4 g/m²^3-152
	1.92 g/m²^3-153
MRC AML 10	3.6 g/m²^3-150	5 g/m²^3-152	—	—	—	49
	1 g/m²^3-152
MRC AML 12	7.2 g/m²^3-150	6 g/m²^3-152	—	—	—
Good/standard risk	2 g/m²^3-152
CALGB 9621	0.7-1.4 g/m²^3-150	—	16-48 g/m²^3-152	—	—	51
AML HD93/98-A	1.4 g/m²^3-150	—	—	18-42 g/m²^3-152	—	2

Study	Cytarabine dose				Comment	Reference
Study	80-200 mg/m²	1 g/m²	2 g/m²	3 g/m²	Comment	Reference
AML-87	0.8-1.6 g/m²^3-150,^3-151	—	—	—	Double induction if no CR after first course	43
	3.8 g/m²^3-151,^3-152
	12.24 g/m²^3-151,^3-153
AML-89	0.32-0.96 g/m²^3-150 or	—	—	—	Double induction if no CR after first course	44
	0.8-2.4 g/m²^3-150,^3-151
	2.12 g/m²^3-152 or
	3.8 g/m²^3-151,^3-152
	6.12 g/m²^3-151,^3-153
AML-92	2 g/m²^3-150,^3-151	—	—	—	Postremission therapy not reported	45
HOVON-29	1.4 g/m²^3-150	12 g/m²^3-150	—	—	—	46
HOVON-4	1.4 g/m²^3-150	12 g/m²^3-150	—	—	—	47
AML-11	1.4-2.8 g/m²^3-150	—	—	—	Double induction if PR after first course	48
	1.4 g/m²^3-152
	1.92 g/m²^3-153
MRC AML 10	3.6 g/m²^3-150	5 g/m²^3-152	—	—	—	49
	1 g/m²^3-152
MRC AML 12	7.2 g/m²^3-150	6 g/m²^3-152	—	—	—
Good/standard risk	2 g/m²^3-152
CALGB 9621	0.7-1.4 g/m²^3-150	—	16-48 g/m²^3-152	—	—	51
AML HD93/98-A	1.4 g/m²^3-150	—	—	18-42 g/m²^3-152	—	2

PR indicates partial remission; and —, no treatment with cytarabine at the corresponding dose level (eg, 3 g/m²) has been administered.

Induction therapy.

Including behenoyl cytarabine instead of cytarabine.

Consolidation therapy.

Maintenance therapy.